Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use

Regimens containing sofosbuvir
(Sovaldi) – including sofosbuvir plus
simeprevir (Olysio) – work well for people
with hepatitis C genotype 1 in real-world use, which to date has included some
of the patients most urgently in need of treatment at the dawn of the
interferon-free era, according to a pair of presentations at the American
Association for